“Adverse Events of Special Interest in Patients With Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study”. 2020. SKIN The Journal of Cutaneous Medicine 4 (5): s67. https://doi.org/10.25251/skin.4.supp.66.